Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy
Wilson L, Cooper D, Goodrich A, Friedman N, Feldman A, Braverman I, Kacinski B. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. International Journal Of Radiation Oncology • Biology • Physics 1994, 28: 829-837. PMID: 8138435, DOI: 10.1016/0360-3016(94)90102-3.Peer-Reviewed Original ResearchConceptsTotal skin electron beam therapySystemic adjuvant therapyRelapse-free survivalDoxorubicin/cyclophosphamide chemotherapyShorter relapse-free survivalElectron beam therapyAdjuvant therapyDermatologic diagnosesBeam therapyCyclophosphamide chemotherapyFollicular mucinosisOverall survivalT2 patientsExtracorporeal photopheresisLymphomatoid papulosisCutaneous relapseTotal skin electron beam radiation therapyCutaneous T-cell lymphoma patientsT-cell lymphoma patientsBetter relapse-free survivalClinical complete responseCohort of patientsElectron beam radiation therapyBeam radiation therapyAdjuvant chemotherapyThe utility of adjuvant psoralen + ultraviolet-a light [PUVA] therapy in maintaining cutaneous remission in T1 and T2 CTCL (mycosis fungoides) treated with total skin electron beam radiation therapy [TSEBT]
Kolenli S, Kacinski B, Quiros P, Wilson L, Heald P, Edelson R, Braverman I. The utility of adjuvant psoralen + ultraviolet-a light [PUVA] therapy in maintaining cutaneous remission in T1 and T2 CTCL (mycosis fungoides) treated with total skin electron beam radiation therapy [TSEBT]. International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 266. DOI: 10.1016/0360-3016(94)90820-6.Peer-Reviewed Original Research